XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Note 2 - Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Apr. 22, 2024
May 31, 2025
Sep. 30, 2025
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Jan. 24, 2025
Amortization of above and below Market Leases     $ 1,244   $ 1,244         $ 3,509 $ 3,731  
Deferred Costs     1,400,000 $ 1,700,000           1,400,000    
Operating Lease, Initial Direct Cost Expense, over Term     126,136   125,302         343,569 369,401  
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation     8,002,915 8,036,496           8,002,915    
Restricted Cash     3,800,000 5,000,000           3,800,000    
Deferred Offering Costs     79,170 0           79,170    
Liabilities, Fair Value Disclosure     0 0           0    
Equity Securities, FV-NI     7,515 $ 206,177           7,515    
Operating Lease, Lease Income     4,108,866   4,640,816         12,423,048 13,754,740  
Payments of Debt Issuance Costs                   333,838 210,661  
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation                   (380,224) (658,434)  
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation                   (11,087,304) (9,317,275)  
Revision of Prior Period, Error Correction, Adjustment [Member]                        
Operating Lease, Lease Income         165,983           597,859  
Revision of Prior Period, Adjustment [Member]                        
Payments of Debt Issuance Costs                     210,661  
Payments for Prepayment Penalty                     171,734  
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation                     (382,396)  
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation                     382,396  
Conduit Pharmaceuticals Inc [Member]                        
Equity Securities, FV-NI     $ 7,515             $ 7,515    
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 540,000   540,000             540,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 3.12                      
Warrants and Rights Outstanding, Term (Year) 2 years                      
Warrant or Right, Exercisable Period (Year) 1 year                      
Conduit Pharmaceuticals Inc [Member]                        
Lock-up Agreement, Shares (in shares) 2,700,000                      
Investment Owned, Balance, Shares (in shares) 4,015,250     2,944,514               29,445
Equity Securities, FV-NI     $ 7,515 $ 200,000           $ 7,515    
Conduit Pharmaceuticals Inc [Member] | CDT Common Stock [Member]                        
Proceeds from Sale, Maturity and Collection of Investments   $ 13,990             $ 13,990      
Fair Value, Inputs, Level 1 [Member]                        
Marketable Securities       0                
Commercial Property [Member]                        
Impairment of Real Estate                   4,400,000 4,400,000  
Model Home [Member]                        
Impairment of Real Estate                   $ 900,000 900,000  
Maximum [Member] | Furniture and Fixtures [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)     5 years             5 years    
Minimum [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)     1 year             1 year    
Minimum [Member] | Leasehold Improvements [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)     1 year             1 year    
Lease Intangibles [Member] | Maximum [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)     10 years             10 years    
Finite-lived Intangibles, Other Than Lease Intangibles [Member]                        
Amortization of Intangible Assets     $ 4,382   4,382         $ 13,145 $ 13,145  
Finite-lived Intangibles, Other Than Lease Intangibles [Member] | Revision of Prior Period, Error Correction, Adjustment [Member]                        
Amortization of Intangible Assets       $ 159,845 $ 165,983 $ 211,256 $ 220,620 $ 194,884